Journal: Developmental cell

Article Title: In vitro and in vivo development of the human airway at single cell resolution

doi: 10.1016/j.devcel.2020.01.033

Figure Lengend Snippet: A) Overview of experimental design. B) Protein stain for TP63 (green), EGFR (pink), F3 (white) and DAPI (blue) in organoids treated for 3 days of DSA followed by 7 days of DSI. Scale bar represents 50 μm. C) EGFR/F3 and control FACS plots for 1 representative biological replicate (n=3 biological replicates). D-E) Protein staining for TP63 (red, nuclear) and quantification of TP63+ cells/total cells on sorted cells spun onto a glass slide using a Cytospin. Error bars represent the mean +/− the standard error of the mean. N=3 biological replicates, shown as 3 separate colors on the plot. F) Quantification of the percentage of cells in each organoid containing positive protein staining for canonical cell type markers in unsorted organoids versus organoids that were grown from isolated EGFR+/F3+ cells. N=3 biological replicates per group and n=3 technical replicates (individual organoids) per biological replicate. A total of 198 cells were counted for the EGFR-/F3- group, 110 cells counted for EGFR+/F3- group, 38 cells counted for the EGFR-/F3+ group, and 88 cells counted for the EGFR+/F3+ group. G) Protein staining of organoids derived from EGFR/F3 sorted cells for secretory marker SCGB1A1 (pink), multiciliated markers AcTUB+ and FOXJ1+ (white), epithelial marker KRT8 (green), basal cell marker TP63 (pink), goblet cell marker MUC5AC (white) and DAPI (blue). Data shown from a single biological replicate and is representative of N=3 biological replicates. Scale bars represents 50 μm. H)GFP (green), RFP (red) and brightfield images of whole organoids 11 days after re-plating and mixing EGFR/F3 sorted cells from GFP and RFP expressing groups. N=1 biological replicate with n=6 technical replicates (wells of mixed organoids). Data shown from a single experiment and is representative of n=3 experiments. Scale bar represents 200 μm (top row) and 100 μm (bottom row).

Article Snippet: Human anti-EGFR-APC (FACS) , Milteny , 130-110-587.

Techniques: Staining, Control, Isolation, Derivative Assay, Marker, Expressing

Journal: Developmental cell

Article Title: In vitro and in vivo development of the human airway at single cell resolution

doi: 10.1016/j.devcel.2020.01.033

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Human anti-EGFR-APC (FACS) , Milteny , 130-110-587.

Techniques: Transduction, Control, Virus, Plasmid Preparation, Recombinant, RNAscope, Multiplex Assay, In Situ Hybridization, Generated, Software

Journal: Cancers

Article Title: Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures

doi: 10.3390/cancers13195009

Figure Lengend Snippet: TNBC tissues are represented by different patient-specific signaling signatures, majority of which do not include EGFR. ( A ) Fold changes in expression levels of EGFR and pEGFR in TNBC and non-TNBC tumors are shown. Y1068 and Y1173 are EGFR phosphorylation sites; ( B ) Examples for patient-specific sets of active unbalanced processes are shown. Each sample harbors a set of 1–3 active unbalanced processes (PaSSS), represented schematically by a barcode. In each barcode active unbalanced processes are represented by black or gray squares, inactive white. Negative/positive amplitude denotes how the patients are correlated with respect to a particular process. Suggested PaSSS-based therapies appear below each barcode; ( C ) Heterogeneity index of 3 subgroups, represented by a ratio between the number of distinct PaSSSs and the number of samples in each subset, is shown for the TNBC subset of tissues, the entire set (3467 samples from 11 cancer types) and the subset of non-TNBC samples. (Abbreviations: TNBC—Triple Negative Breast Cancer, PaSSS—Patient-specific signaling signature, EGFR—Epidermal Growth Factor Receptor, VEGFR2—Vascular Endothelial Growth Factor Receptor 2, Her2—Human Epidermal growth factor Receptor 2, Src—Proto-oncogene tyrosine-protein kinase Src).

Article Snippet: The following conjugated antibodies were used: anti-p-EGFR (Y1068) (R&D Systems, Minneapolis, MN, USA, cat. no. IC3570G), anti-p-ERK2 (Thr202/Tyr204) (BioLegend, San Diego, CA, USA, cat. No. 675503), anti-p-S6 (Ser235/236) (BioLegend, cat. no. 608605), and anti-GAPDH (Santa Cruz Biotechnology, Dallas, Texas, USA, cat. no. sc-47724AF594).

Techniques: Expressing, Phospho-proteomics